Get the Stockscreener App
28.79
0.17%
-0.05
After Hours:
29.00
0.21
+0.73%
Ceribell Inc stock is traded at $28.79, with a volume of 67,941.
It is down -0.17% in the last 24 hours and up +9.89% over the past month.
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.
See More
Previous Close:
$28.84
Open:
$28.94
24h Volume:
67,941
Relative Volume:
0.64
Market Cap:
$1.03B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+9.43%
1M Performance:
+9.89%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$28.74
$29.34
1-Week Range:
$26.71
$29.34
52-Week Range:
$24.10
$29.53
Ceribell Inc Stock (CBLL) Company Profile
Name
Ceribell Inc
Sector
Industry
Phone
(800) 436-0826
Address
360 N. PASTORIA AVENUE, SUNNYVALE
Compare CBLL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CBLL
Ceribell Inc
|
28.79 | 1.03B | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
118.77 | 206.00B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
392.15 | 149.49B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
90.66 | 133.62B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
86.54 | 110.97B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
71.35 | 42.08B | 6.60B | 4.16B | 490.10M | 6.93 |
Ceribell Inc Stock (CBLL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-24 | Initiated | BofA Securities | Buy |
| Nov-05-24 | Initiated | Canaccord Genuity | Buy |
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Initiated | William Blair | Outperform |
Ceribell Inc Stock (CBLL) Latest News
CeriBell: Healthcare Technology Stock With A Promising Growth Outlook (NASDAQ:CBLL) - Seeking Alpha
Ceribell appoints Rodenbush as CPO, Price as SVP of Marketing - TipRanks
Ceribell Appoints Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing - The Manila Times
Ceribell Strengthens Leadership Team with Key AI Medical Device Executives | CBLL Stock News - StockTitan
Meet the biophysicist whose seizure-detection company is using AI to get a better read on people's brains - Fast Company
FY2024 EPS Estimates for CeriBell Reduced by William Blair - MarketBeat
William Blair Estimates CeriBell's Q1 Earnings (NASDAQ:CBLL) - MarketBeat
Ceribell revenue increases 48% to USD 17.2M in Q3 2024 - Medical Buyer
Ceribell, Inc. Reports Strong Q3 2024 Growth - Yahoo Finance
Ceribell price target raised to $31 from $30 at Canaccord - TipRanks
CeriBell (NASDAQ:CBLL) Price Target Raised to $31.00 at Canaccord Genuity Group - MarketBeat
CeriBell's (NASDAQ:CBLL) Quiet Period To End on November 20th - MarketBeat
CeriBell’s Quiet Period To End on November 20th (NASDAQ:CBLL) - Defense World
Ceribell Reports Third Quarter 2024 Financial Results - GlobeNewswire
CeriBell, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Ceribell Receives Authority to Operate from the U.S. Department of Veterans Affairs - GlobeNewswire
Ceribell Secures VA Authorization, Expands AI-Powered EEG Tech to Veterans Hospitals | CBLL Stock News - StockTitan
Q3 Earnings Estimate for CeriBell Issued By William Blair - Defense World
Brokerages Set CeriBell (NASDAQ:CBLL) PT at $31.00 - Defense World
Ceribell started with bullish ratings by J.P. Morgan, Canaccord - MSN
Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum - The Manila Times
FMR LLC Acquires New Stake in CeriBell Inc - GuruFocus.com
Ceribell initiated with a Buy at BofA on ‘differentiated AI algorithm’ - Yahoo Finance
Ceribell stock a buy as JPMorgan highlights disruptive tech in $3B seizure market - Investing.com Australia
Ceribell initiated with an Overweight at JPMorgan - MSN
Ceribell started with bullish ratings by J.P. Morgan, Canaccord (NASDAQ:CBLL) - Seeking Alpha
TD Cowen starts coverage on Ceribell stock with Buy, highlights innovative tech - Investing.com Canada
This Eaton Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
A&O Shearman advises on initial public offering of Ceribell, Inc. - A&O Shearman
Ceribell to Report Third Quarter 2024 Financial Results on November 12, 2024 - WV News
Ceribell’s stock soars 36% in trading debut after pricing IPO at top of range - MSN
Septerna Shares Jump 19% After IPO Shows Biotech Still Hot - Bloomberg
CeriBell Shares Rise 47% to Lead Trio of Life Sciences IPOs - MSN
CeriBell: An Interesting EEG Play Going Public (NASDAQ:CBLL) - Seeking Alpha
TPG GP A, LLC Acquires New Stake in CeriBell Inc - GuruFocus.com
Ceribell EEG system linked to improved patient outcomes - Investing.com India
Ceribell EEG system linked to improved patient outcomes By Investing.com - Investing.com Australia
Ceribell director Juliet Tammenoms Bakker buys $4.03m in stock By Investing.com - Investing.com Australia
Ceribell director Juliet Tammenoms Bakker buys $4.03m in stock - Investing.com
New Clinical Evidence Links Ceribell Point-of-Care EEG to Shorter Hospital Stays and Better Functional Outcomes Compared to Conventional EEG - PR Newswire
CeriBell closes upsized IPO - Medical Buyer
Ceribell Inc Stock (CBLL) Financials Data
There is no financial data for Ceribell Inc (CBLL). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.73%
0.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):